Captor Therapeutics Spolka Akcyjna (WSE:CTX)

Poland flag Poland · Delayed Price · Currency is PLN
47.00
+3.50 (8.05%)
Oct 24, 2025, 5:03 PM CET
8.05%
Market Cap259.85M
Revenue (ttm)11.10M
Net Income (ttm)-39.48M
Shares Out5.53M
EPS (ttm)-7.77
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume19,954
Average Volume12,715
Open44.20
Previous Close43.50
Day's Range43.50 - 48.50
52-Week Range31.20 - 72.20
Beta0.71
RSI72.83
Earnings DateNov 24, 2025

About WSE:CTX

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has various therapeutic molecules in the preclinical stage. The company was incorporated in 2015 and is headquartered in Wroclaw, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 91
Stock Exchange Warsaw Stock Exchange
Ticker Symbol CTX
Full Company Profile

Financial Performance

In 2024, WSE:CTX's revenue was 15.83 million, an increase of 19.88% compared to the previous year's 13.20 million. Losses were -38.43 million, -45.56% less than in 2023.

Financial Statements

News

There is no news available yet.